Zevra Therapeutics Inc. (ZVRA) Stock Forecast & Price Target
Zevra Therapeutics Inc. · NASDAQ
$9.71+0.18 (+1.94%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering Zevra Therapeutics Inc, 8 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $18.00 to $35.00, a moderate spread. The average target of $27.88 sits 187% above the current $9.71. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.18 next quarter toward $1.11 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Moderate Buy
Strong Buy00%
Buy8100%
Hold00%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to Zevra Therapeutics Inc.
As of Jul, 8 of 8 firms rate ZVRA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ZVRA EPS & revenue forecast
EPS · NEXT QUARTER
$0.18
Range $0.13 – $0.21 · 4 analysts · -1875% YoY
Next period, 4 analysts expect Zevra Therapeutics Inc. to earn $0.18 a share (range $0.13 – $0.21), versus $-0.01 a year earlier. Full-year consensus is $1.22, growing to $1.11 the year after.
REVENUE · NEXT QUARTER
$36.1M
Range $33.0M – $42.3M · 4 analysts · +39% YoY
Revenue is expected to reach $36.1M (range $33.0M – $42.3M), +38.6% year-over-year. Full-year consensus is $145.7M, rising to $176.0M next year.
Top analysts covering Zevra Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ZVRA.
#1
Jason Butler
JMP Securities · Rank #22
Buy
$25.00+157.5% to target
Overall win rate
57%
+ Follow
#2
Oren Livnat
HC Wainwright & Co. · Rank #142
Buy
$20.00+106.0% to target
Overall win rate
54%
+ Follow
#3
Louise Chen
Cantor Fitzgerald · Rank #156
Buy
No targeton ZVRA
Overall win rate
43%
+ Follow
#4
Kristen Kluska
Cantor Fitzgerald · Rank #162
Buy
$34.00+250.2% to target
Overall win rate
38%
+ Follow
#5
Sumant Kulkarni
Canaccord Genuity · Rank #278
Buy
$29.00+198.7% to target
Overall win rate
39%
+ Follow
ZVRA stock forecast FAQ
What is ZVRA's average 12-month price target?+
The 8 analysts with a live target average $27.88 for Zevra Therapeutics Inc. over the next 12 months, ranging from a $35.00 high to a $18.00 low.
Is ZVRA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 8 analyst ratings, 8 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ZVRA?+
The Street-high target is $35.00 (Maxim Group), and the Street-low is $18.00 (JMP Securities). The average of all 8 active targets is $27.88.
How many Wall Street analysts cover ZVRA?+
8 analysts have an active rating on Zevra Therapeutics Inc., and 8 firms carry a live 12-month price target.
Who is the most accurate analyst covering ZVRA?+
Among analysts who currently cover ZVRA, Jason Butler of JMP Securities has the strongest overall Quantellect track record (Rank #22). Their current call is Buy with a $25.00 target.
What is Zevra Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $0.18 per share (range $0.13 – $0.21) across 4 analysts. Full-year EPS is projected at $1.22, rising to $1.11 the following year.
How much revenue is Zevra Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $36.1M (range $33.0M – $42.3M). Full-year revenue is projected at $145.7M, growing to $176.0M next year.
Have analysts been upgrading or downgrading ZVRA lately?+
As of Jul, 8 of 8 firms rate ZVRA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ZVRA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
